$CAH (Cardinal Health, Inc.)

$CAH {{ '2015-11-02T13:21:23+0000' | timeago}} • Announcement

$CAH's CEO, George Barrett, commenting on 1Q16 results said, "With this strong first quarter behind us and greater line of sight to certain drivers for the year, we are raising our FY16 non-GAAP diluted EPS guidance range to $5.15-5.35 from a prior range of $4.85-5.05. This new range represents an 18-22% growth rate compared to fiscal 2015."

$CAH {{ '2017-08-09T20:21:11+0000' | timeago}} • Announcement

$CAH has declared a quarterly dividend of $0.4624 per share. The dividend is payable on October 15, 2017, to shareholders of record on October 2, 2017.

$CAH {{ '2017-07-31T12:06:51+0000' | timeago}} • Announcement

$CAH closed purchase of $MDT's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business for $6.1Bil. The acquisition was funded with a combination of $4.5Bil in new senior unsecured notes, existing cash and borrowings under $CAH's existing credit arrangements.

$MDT {{ '2017-07-31T12:02:15+0000' | timeago}} • Announcement

$MDT completes the sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery division to $CAH for $6.1Bil in cash. The company expects modest dilution on a net basis to its FY18 non-GAAP EPS of approx. $0.18.

$MDT {{ '2017-05-25T11:22:16+0000' | timeago}} • Announcement

In FY18, $MDT expects constant currency revenue growth to be in the range of 4% to 5%. Medtronic sees full-year non-GAAP diluted EPS to grow by 9-10%. Fiscal year guidance does not include the impact of the divestiture of a portion of its Patient Monitoring and Recovery division to $CAH, expected to close in 2Q18.

$CAH {{ '2017-05-03T21:40:57+0000' | timeago}} • Announcement

$CAH BoD approved a 3% increase in quarterly dividend from $0.4489 per share to $0.4624 per share. The dividend is payable on July 15 to shareholders of record on July 3.

$CAH {{ '2017-05-01T19:40:41+0000' | timeago}} • Webcast

$CAH expects closer to 90% of its branded agreements, currently over 85%, to be non-contingent to inflation by FY17 end, if not by the end of FY18.

$CAH {{ '2017-05-01T18:58:25+0000' | timeago}} • Webcast

$CAH sees to incur tax and some reserve adjustments in FY17 but not in FY18. Cardinal Health also expects incremental expenses over the next couple of years due to the planned Pharma Distribution IT refresh project rollout, particularly next year.

$CAH {{ '2017-05-01T11:44:43+0000' | timeago}} • Announcement

3Q17 revenue for the Pharmaceutical segment rose 3% to $28.4Bil at $CAH, due to the performance from the Specialty business and growth from Pharmaceutical Distribution customers. Medical segment revenue was up 9% to $3.4Bil. CAH now sees FY17 non-GAAP EPS from continuing ops at the bottom of its previous guidance range of $5.35-5.50.

$CAH {{ '2017-05-01T11:43:33+0000' | timeago}} • Announcement

$CAH's revenue inched 4% up to $31.8Bil in 3Q17, as the health care services company's net income slipped 1% to $381MM from last year's $386MM. Earnings rose 3% to $1.20 per diluted share from last year's $1.17 a share, benefitted from a lower effective tax rate and fewer weighted average shares outstanding.

$CAH {{ '2017-04-19T12:13:05+0000' | timeago}} • Announcement

$CAH expects generic deflation to moderate to mid-single digits in FY18 but this deflation is still a headwind for the Pharmaceutical segment for the year.  This, combined with certain discrete items could result in an estimated Pharmaceutical segment profit decline in the high-single digits versus FY17.

$CAH {{ '2017-04-19T12:12:44+0000' | timeago}} • Announcement

For FY18, $CAH expects adjusted EPS to be flat to down mid-single digits. $CAH also expects a significant increase in the Medical segment's profit. $CAH believes certain company-specific discrete items will have a negative impact on EPS of at least $0.50. For FY19, $CAH expects adjusted EPS to grow at least high-single digits vs. FY18.

$CAH {{ '2017-04-19T12:12:28+0000' | timeago}} • Announcement

$CAH is updating its FY17 adjusted EPS guidance. $CAH believes FY17 adjusted EPS from continuing operations will be at the bottom of its previous guidance range of $5.35-5.50. This takes into consideration generic deflation, which the company now expects to be in the low-double digits for FY17.

$CAH {{ '2017-04-18T12:35:44+0000' | timeago}} • Announcement

$CAH expects the $MDT portfolio acquisition to be accretive to adjusted diluted EPS by more than $0.55 per share in FY19, and increasingly accretive thereafter. By the end of FY20, the company assumes synergies will exceed $150MM annually.

$CAH {{ '2017-04-18T12:35:25+0000' | timeago}} • Announcement

$CAH expects the patient product portfolio acquisition from $MDT to be accretive to adjusted diluted EPS from continuing operations by more than $0.21 per share in FY18, which includes about $100MM of inventory step-up costs during the first few quarters following closing.

$CAH {{ '2017-04-18T12:35:04+0000' | timeago}} • Announcement

$CAH agreed to acquire $MDT’s Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1Bil in cash. The purchase price does not include cash tax benefits of at least $100MM. The deal is expected to be financed with a combination of $4.5Bil in new senior unsecured notes and existing cash and is expected to close in 1Q18.

$MDT {{ '2017-04-18T12:23:11+0000' | timeago}} • Announcement

$MDT agreed to sell a portion of its PMR division to $CAH. The transaction is expected to result in an immediate positive impact to $MDT’s comparable, constant currency revenue growth rate and adjusted comparable, constant currency operating margin of about 50BP each. $MDT expects a modest dilution to FY18 adjusted EPS of about $0.12-0.18.

$MDT {{ '2017-04-18T12:22:47+0000' | timeago}} • Announcement

$MDT entered into an agreement with $CAH to sell its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group for $6.1Bil in cash, with total after-tax proceeds estimated to be about $5.5Bil. The deal is expected to close in 2Q18.

$CAH {{ '2017-02-07T15:45:07+0000' | timeago}} • Webcast

$CAH said it continues to grow the number of products and product categories in Cardinal Health Brand. The company now offers with 19,000 stock keeping units (SKUs) in 110 product families.

$CAH {{ '2017-02-07T15:33:26+0000' | timeago}} • Webcast

$CAH generated $554MM in operating cash flow during 2Q17. Cash balance including short-term investments at the end of the quarter was $2.1Bil, with $552MM held outside the United States.

$CAH {{ '2017-02-07T12:18:33+0000' | timeago}} • Announcement

$CAH lowered its FY17 non-GAAP EPS guidance to $5.35-5.50 from $5.40-5.60. This now reflects non-GAAP EPS growth of 2-5%. As previously disclosed, $CAH does not provide GAAP EPS outlook, as it is unable to reliably forecast most of the items that are excluded from GAAP EPS to calculate non-GAAP EPS.

Recent Transcripts

ORCL (Oracle Corporation)
Thursday, September 14 2017 - 9:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
AMS (American Shared Hospital Services)
Thursday, August 10 2017 - 7:00pm
MYL (Mylan N.V.)
Wednesday, August 9 2017 - 2:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
ABC (AmerisourceBergen Corporation)
Thursday, August 3 2017 - 12:30pm
NUS (Nu Skin Enterprises Inc.)
Wednesday, August 2 2017 - 9:00pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
HUM (Humana Inc.)
Wednesday, August 2 2017 - 1:00pm
CAH (Cardinal Health, Inc.)
Wednesday, August 2 2017 - 12:30pm
HLF (Herbalife Ltd.)
Tuesday, August 1 2017 - 9:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
HSKA (Heska Corporation)
Monday, July 31 2017 - 3:00pm
OMCL (Omnicell, Inc.)
Thursday, July 27 2017 - 8:30pm
ABAX (Abaxis, Inc.)
Thursday, July 27 2017 - 8:15pm
MCK (McKesson Corporation)
Thursday, July 27 2017 - 12:30pm
SNN (Smith & Nephew plc)
Thursday, July 27 2017 - 8:00am
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm

AlphaGraphics you may like